Regeneron to Buy 23andMe for $256M Amid Growing Data Privacy Concerns
Biotechnology giant Regeneron Pharmaceuticals has emerged as the successful bidder in the bankruptcy auction for genetic testing pioneer 23andMe, offering $256 million for the majority…